Koji Izutsu, Hisashi Kato, Naohiro Sekiguchi, Tomoaki Fujisaki, Toshiro Kawakita, Naoshi Obara, Kosei Matsue, Mitsutaka Nishimoto, Tomoyoshi Hatayama, Mitsuo Inagaki, et al. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia. International journal of hematology. 2024
Yumiko Maruyama, Hidekazu Nishikii, Naoki Kurita, Tatsuhiro Sakamoto, Keiichiro Hattori, Yasuhito Suehara, Yasuhisa Yokoyama, Takayasu Kato, Naoshi Obara, Mamiko Sakata-Yanagimoto, et al. Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide - A retrospective single-center study with a Japanese cohort. Blood cells, molecules & diseases. 2024. 105. 102820-102820
Naoshi Obara, Kensuke Usuki, Takeshi Hayashi, Masato Fujii, Takayuki Ikezoe. Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors. International journal of hematology. 2024. 119. 3. 255-264
Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu, et al. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. Cancer reports (Hoboken, N.J.). 2024. 7. 1. e1938
Haruka Momose, Naoki Kurita, Hidekazu Nishikii, Nozomi Yusa, Kazuaki Yokoyama, Eigo Shimizu, Seiya Imoto, Toru Nanmoku, Yumiko Maruyama, Tatsuhiro Sakamoto, et al. [Durable remission of T-cell prolymphocytic leukemia with CLEC16A::IL2 after allogeneic hematopoietic stem cell transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2024. 65. 1. 35-40